News coverage about Calithera Biosciences (NASDAQ:CALA) has been trending positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Calithera Biosciences earned a daily sentiment score of 0.27 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Several research firms have commented on CALA. BidaskClub cut Calithera Biosciences from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Zacks Investment Research cut Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. HC Wainwright restated a “buy” rating and issued a $19.00 price target (up previously from $14.00) on shares of Calithera Biosciences in a report on Monday, June 12th. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $20.00 price target (up previously from $15.00) on shares of Calithera Biosciences in a report on Tuesday, June 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $15.50.

Calithera Biosciences (NASDAQ CALA) traded up 0.67% during trading on Monday, reaching $14.95. The company had a trading volume of 467,807 shares. The company’s market capitalization is $527.65 million. The stock has a 50 day moving average of $15.97 and a 200-day moving average of $12.36. Calithera Biosciences has a 12 month low of $2.20 and a 12 month high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.14. The company had revenue of $4.19 million for the quarter, compared to analyst estimates of $1.40 million. Equities research analysts expect that Calithera Biosciences will post ($0.89) EPS for the current fiscal year.

In other news, VP Keith Orford sold 2,120 shares of the stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $18.31, for a total transaction of $38,817.20. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last three months, insiders have sold 3,470 shares of company stock worth $61,817. 16.30% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/07/calithera-biosciences-nasdaqcala-earning-favorable-press-coverage-study-finds-updated-updated-updated.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Insider Buying and Selling by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.